Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Academic Article uri icon

Overview

abstract

  • Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity. The median nadir leukocyte count was 1.75 cells/mm3, neutrophil count was 1.55 cells/mm3, hemoglobin was 8.75 gm/dl, and platelet count was 20,500 cells/mm3. Topotecan is not efficacious in the treatment of cisplatin-refractory GCT.

publication date

  • January 1, 1995

Research

keywords

  • Antineoplastic Agents
  • Camptothecin
  • Drugs, Investigational
  • Germinoma

Identity

Scopus Document Identifier

  • 0028860716

Digital Object Identifier (DOI)

  • 10.1007/BF00872866

PubMed ID

  • 8617580

Additional Document Info

volume

  • 13

issue

  • 2